Prothena (FRA:0PT) Cyclically Adjusted PB Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0PT Prothena Corp PLC FRA:0PT
74 GF Score
Price €7.12
GF Value €10.76
! 2 Warning Signs
View Full Analysis

What is Prothena Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Prothena  (FRA:0PT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Prothena Cyclically Adjusted PB Ratio Related Terms


Prothena Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Prothena's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prothena Cyclically Adjusted PB Ratio Chart

Prothena Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.10 6.09 3.56 1.48 0.88

Prothena Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.84 0.84 0.88 0.94

FRA:0PT vs EVMN, EDIT, CCCC: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Prothena's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prothena Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Prothena's Cyclically Adjusted PB Ratio falls into.


FRA:0PT
74GF Score
Prothena Corp PLC FRA:0PT
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prothena Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Prothena's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Prothena's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=4.849/128.6700*128.6700
=4.849

Current CPI (Jun. 2026) = 128.6700.

Prothena Quarterly Data

Book Value per Share CPI Adj_Book
201609 10.358 100.274 13.291
201612 9.969 99.676 12.869
201703 12.224 100.374 15.670
201706 11.190 100.673 14.302
201709 9.819 100.474 12.575
201712 8.812 100.075 11.330
201803 8.362 100.573 10.698
201806 7.655 101.072 9.745
201809 7.336 101.371 9.312
201812 7.088 100.773 9.050
201903 6.973 101.670 8.825
201906 6.665 102.168 8.394
201909 6.648 102.268 8.364
201912 6.094 102.068 7.682
202003 5.824 102.367 7.320
202006 5.230 101.769 6.612
202009 4.475 101.072 5.697
202012 3.767 101.072 4.796
202103 4.518 102.367 5.679
202106 5.411 103.364 6.736
202109 9.095 104.859 11.160
202112 8.783 106.653 10.596
202203 8.438 109.245 9.938
202206 8.323 112.779 9.496
202209 8.626 113.504 9.779
202212 11.186 115.436 12.468
202303 10.613 117.609 11.611
202306 9.967 119.662 10.717
202309 10.869 120.749 11.582
202312 9.467 120.749 10.088
202403 8.659 120.990 9.209
202406 10.097 122.318 10.621
202409 8.898 121.594 9.416
202412 8.736 122.439 9.181
202503 7.528 123.405 7.849
202506 5.133 124.492 5.305
202509 4.664 124.810 4.808
202512 4.436 125.770 4.538
202603 5.112 127.830 5.146
202606 4.849 128.670 4.849

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Prothena (FRA:0PT) Overvalued in 2026?

Based on GuruFocus' analysis, Prothena stock appears to be undervalued. The current stock price of €7.12 is trading 33.8% below its estimated GF Value™ of €10.76.

Key valuation signals for FRA:0PT:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €10.76 vs. price of €7.12 (33.8% below fair value)
  • GF Score™: 74/100 with 2 warning signs

No single metric tells the full story. See the FRA:0PT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Prothena Business Description

Other Exchanges PRTA:USA0Y3M:UK
Address 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, Dublin, IRL, D02 VK60
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
74GF Score

Get the complete analysis for FRA:0PT

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.12
Price
€10.76
GF Value